Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

With Parity Pricing, Gilead Relies On Genvoya Safety To Convert From Stribild

This article was originally published in The Pink Sheet Daily

Executive Summary

Genvoya includes a much smaller dose of tenofovir than Stribild, allowing for smaller pills, while its label also includes a number of safety advantages that Gilead can use in marketing.

Advertisement

Related Content

Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos
When Will Gilead Make Its M&A Move?
2Q Pharma Results Preview: What Lies Ahead
The New Quad: FDA Approves Gilead’s 4-In-1 HIV Pill Stribild

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register